logo
Menu
Innovation Observatory > Reports > Skin Disease, Burns and Wound Care

Results

Drugs

May 2018

Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis

Dupilumab is a monoclonal antibody medicine that is currently in development as an injection under the skin (subcutaneous) for the treatment of moderate to severe AD in children. Dupilumab is already licensed in the UK for the treatment of moderate-to-severe atopic dermatitis in adults. If licensed, dupilumab will offer an additional treatment option for children aged 12 years to 17 years with moderate to severe atopic dermatitis uncontrolled on current therapies.

Drugs

March 2018

Rituximab for Pemphigus Vulgaris

Corticosteriods (anti-inflammatory medicines) are usually used for the treatment of PV. Most people will need to take corticosteroids in addition to another medication to help improve the effectiveness and minimise the doses and side effects of corticosteroids. Rituximab is currently being investigated as a treatment option for PV. Rituximab binds specifically to a protein called CD20 located on pre-B and mature B lymphocytes inducing death of these cells. If licensed, rituximab may offer an additional treatment option for patients with PV after failure of systemic steroids and steroid sparing agents to control the disease.

Drugs

November 2017

Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking an important molecule in inflammation from a process which allows the body’s immune cells (specifically T-cells) to activate other immune cells and release substances which cause inflammation (cytokines).

Drugs

November 2017

Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis

Risankizumab is a drug which is injected into the skin. It works in a unique way by blocking a specific process which allows the body’s immune cells (specifically T-cells) from attacking and damaging the skin.

Drugs

October 2017

Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

  The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to …

Drugs

April 2017

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Certolizumab pegol is an anti-TNF (anti-tumour necrosis factor) drug. It works by blocking the action of TNF protein and which reduces inflammation. It is currently licensed for the treatment of several chronic inflammatory conditions, including Crohn’s Disease, rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. If licensed for chronic plaque psoriasis in adults it will offer …

Drugs

January 2017

Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light

Afamelanotide is a new drug to treat generalised vitiligo. Vitiligo is a long-term condition where white patches develop on the skin, because of a lack of pigment in the skin. This condition may cause significant psychological distress. Afamelanotide is administered as an implant once every 28 days with NB-UVB light therapy administered 2-3 times per …

Drugs

September 2016

Cryopreserved human placental tissue (Stravix) for wound repair

Cryopreserved human placental tissue is a new treatment to aid the healing of wounds that may reduce inflammation and scarring. Skin damage through cuts, burns or surgery are a source of discomfort, inflammation and scarring, and can also lead to infections. Cryopreserved human placental tissue includes molecules and materials expected to aid wound healing as …

Drugs

July 2016

Dupilumab for moderate to severe atopic dermatitis – second line

Dupilumab is a new injection for the treatment of atopic dermatitis. Some studies have suggested that dupilumab can help treat the symptoms of moderate to severe atopic dermatitis that is not responding to treatment with ointments or creams.

Drugs

May 2016

Botulinum toxin A (Dysport) for hyperhidrosis of the axillae

Hyperhidrosis is the medical term for excessive sweating, most commonly affecting the palms of the hands, soles of the feet and the axillae (armpits). Although hyperhidrosis is not life-threatening, it increases the risk of skin infections and has a significant impact on the quality of life of those affected. Botulinum toxin A is a treatment …

Get Alerts